I just listened to the presentation. I didn't hear anything about an RS, however JJ did say that debt was cleared in 2014 in preparation for 2015 uplisting to NASDAQ. He also said that he thinks Wall Street will understand the company better now that they are in more of a clinical trials phase rather than research and development. One can speculate that based on the current share price and number of outstanding shares, a reverse split will be needed to uplist. I think it could work out well in the long run as long as they keep making progress on trials. One of the reasons why reverse splits often don't go well is that they are done by companies already going downhill as a desperation move to avoid delisting. A reverse split combined with an uplisting by an emerging company is a good thing.
News 
Market Data 
Discover 
